Copyright
©The Author(s) 2017.
World J Hepatol. Jul 8, 2017; 9(19): 850-856
Published online Jul 8, 2017. doi: 10.4254/wjh.v9.i19.850
Published online Jul 8, 2017. doi: 10.4254/wjh.v9.i19.850
Table 2 Predictors of composite clinical endpoint (liver related death, hepatocellular carcinoma, liver decompensation) using Multivariate Cox Regression
| Variable | Follow-up from the baseline Hepascore | Follow-up from the second Hepascore | ||
| P | Hazard ratio (95%CI) | P | Hazard ratio (95%CI) | |
| Baseline Hepascore | < 0.001 | 5.85 (2.25-15.18) | 0.020 | 12.86 (1.49-111.17) |
| Second Hepascore | - | - | 0.891 | 3288.82 (0.0-4.6E + 53) |
| Delta Hepascore | - | - | 0.013 | 4.77 (1.35-16.45) |
- Citation: Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856
- URL: https://www.wjgnet.com/1948-5182/full/v9/i19/850.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i19.850